clonoSEQ testing for patients with MCL is currently available for clinical use as a laboratory-developed test performed at ...

In a statistical analysis, Brukinsa resulted in fewer cases of disease progression or death and resulted in lower overall healthcare costs than Imbruvica in patients with chronic lymphocytic leukemia.

SGN-CD19A demonstrated anti-tumor activity across a panel of cell lines derived from multiple B-cell lymphoma and leukemia subtypes ... lymphoid tissue; MCL: Mantle cell lymphoma; MTD: Maximum ...

Castleman disease (CD) is a rare, non-clonal lymphoproliferative disorder that manifests with a wide range of histologic and clinical features. It is classified clinically into unicentric (UCD ...

SAN FRANCISCO, April 08, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of ...

NX-5948 assigned the nonproprietary name "bexobrutideg"U.S. FDA Orphan Drug Designation granted to bexobrutideg for the treatment of Waldenström macroglobulinemiaAchieved $7M in milestones and a $15M ...

On March 28, the FDA approved Imfinzi for use in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single-agent Imfinzi as adjuvant treatment after radical cystectomy, ...

Wegovy and Zepbound are just the latest drug dyads to face-off in the competitive pharma market, continuing a legacy of ...

It has been approved for CLL since 2019 as a monotherapy or in combination with Gazyva, as well as for mantle cell lymphoma. It has become AZ's third biggest-selling cancer medicines, with sales ...

Patients with chronic lymphocytic leukemia (CLL) who experience Richter transformation have a poor prognosis, but ibrutinib ...

Treatment consisted of 4-6 cycles of dose-dense intensive chemotherapy incorporating hyperfractionated ...